Adtran and Iridium strengthen PNT resilience in Europe and Asia-Pacific with Satellite Time and Location technology
24.6.2024 15:00:00 EEST | Business Wire | Press release
Adtran, in partnership with Iridium Communications Inc. (NASDAQ: IRDM), today announced the European and Asia-Pacific launch of its synchronization solutions featuring Iridium® Satellite Time and Location (STL) technology, a significant step in countering growing threats to Global Navigation Satellite Systems (GNSS). Adtran’s OSA 5405-S PTP compact grandmaster clock with STL capabilities and its OSA 5400 STL module are now available to timing network operators in Western Europe, major countries in Eastern Europe, Turkey, and parts of Asia-Pacific, including the majority of Southeast Asia, Japan and South Korea. The solutions enhance the resilience and reliability of critical infrastructure, such as 5G networks, defense systems and many more. Leveraging low-Earth orbit (LEO) satellites to deliver precise and secure positioning, navigation and timing (PNT) services, the devices ensure continuous synchronization even in environments where GNSS is compromised. As a certified Iridium partner, Adtran offers the technology through two distinct purchasing options: an annual service license for optimal flexibility or bundled with equipment for long-term financial planning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240624939927/en/
Adtran’s synchronization solution featuring Iridium® STL services will bring new levels of PNT security to Europe and Asia-Pacific. (Photo: Business Wire)
“The weakness of GNSS signals is increasingly being exploited to create serious problems. As Europe, APAC and the rest of the world have become more dependent on PNT data, attacks on GNSS have only escalated, creating an urgent need to pivot away from the exclusive use of these satellites,” said Michael O’Connor, executive vice president of PNT at Iridium. “By integrating our STL service into Adtran Oscilloquartz devices and making it available across much of Europe and key areas of APAC, we’re providing network operators with valuable new options. They can choose to use our solution as a primary source of timing data in indoor environments, or they can leverage our secure, high-strength LEO signals as a backup source of PNT information when GNSS is unavailable. This offers the strongest ever safeguard against the threats that compromise so many aspects of our daily lives.”
Iridium® STL services harness the power of LEO satellites to transmit encrypted signals that are 1,000 times stronger than those of GNSS, significantly reducing vulnerability to disruptions and manipulation. The technology excels in challenging environments like urban canyons and indoor areas and can penetrate deep into buildings without the need for rooftop antennas. STL services are now a key feature of Adtran’s Oscilloquartz product lineup. The versatile OSA 5405-S PTP grandmaster clock supports STL time services and multi-constellation GNSS, as well as various other timing sources, all within a zero-trust architecture that leverages multiple diverse timing sources for enhanced resilience. Additionally, the OSA 5400 STL module extends these advanced STL/GNSS receiver capabilities to third-party equipment requiring timing, enabling precise, robust synchronization for a wide range of applications.
“We partnered with Iridium to bring the benefits of its STL services to critical timing infrastructure around the world because we share a common goal. We’re committed to making PNT networks as resilient and secure as possible. STL is a powerful solution for fortifying zero-trust architecture and ensuring reliable PNT even when GPS signals fail, making it ideal for both indoor and challenging outdoor locations. By empowering operators of mission-critical networks to access reliable timing in the most demanding environments, we’re also eliminating the need to install outdoor antennas and core through concrete, significantly reducing expenses,” commented Gil Biran, GM of Oscilloquartz, Adtran. “We’re excited to bring these advantages to so many more customers across Europe and APAC. Today’s announcement marks a significant advancement for the network operators and people of these regions, whose daily lives increasingly depend on robust PNT.”
Adtran is making STL services readily available in ways that perfectly align with the evolving needs of modern network infrastructures, offering two purchasing models designed to maximize operational flexibility and support financial planning. The ‘opex model’ provides an annual service license, which is ideal for operators that need adaptable yearly budgeting. Conversely, the ‘capex model’ bundles STL services with essential equipment for 3, 5 or 10 years, facilitating cost amortization similar to traditional GNSS systems. These options make the benefits of LEO satellite signals – whether as a robust primary timing source or a highly reliable backup to GNSS – accessible to sectors where reliable and secure PNT is paramount, including 5G, data centers, smart grids and defense.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240624939927/en/
Contacts
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Rhonda Lambert
+1 256 963 7450
investor@adtran.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom